Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART-CAP: Aggressive Therapy for Coronary Plaque
NCT06280976Phase 4Withdrawn
- Sponsor
- University of Louisville
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Antisense DNA, Nucleic Acid-Directed Small Molecules, Conjugated siRNA
- Countries
- 1
01
Overview
A Phase 4 trial of bempedoic acid + ezetimibe, inclisiran, omega-3-acid triglycerides, empagliflozin, colchicine in coronary artery disease (CAD), atherosclerosis, sponsored by University of Louisville. Planned start Mar 2024; status: withdrawn.
02
Drugs
bempedoic acid + ezetimibeinclisiranomega-3-acid triglyceridesempagliflozincolchicine
03
Conditions
coronary artery disease (CAD)atherosclerosis
Beyond the preview
Go deeper on NCT06280976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280976.